Text Size

Effects of Allergen Inhalation on Adenosine Receptor Expression in Sputum and Peripheral Blood

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2007 by Groningen Research Institute for Asthma and COPD.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
Groningen Research Institute for Asthma and COPD
ClinicalTrials.gov Identifier:
NCT00116311
First received: June 28, 2005
Last updated: March 20, 2007
Last verified: March 2007
History of Changes
  Purpose

The purpose of this study is to determine whether asthmatics have different adenosine receptor expression profiles than healthy controls. We hypothesize that asthmatics will have increased adenosine receptor expression versus control subjects.

We also want to study the effects of allergen inhalation on adenosine receptor expression in asthmatics. We believe that adenosine receptor expression will be upregulated after allergen inhalation.

Both hypotheses are being tested in sputum and peripheral blood.


Condition Intervention
Asthma
Healthy
 Behavioral: allergen inhalation
Behavioral: withdrawal of medication
Procedure: sputum induction

Study Type: Observational
Study Design: Observational Model: Defined Population
Primary Purpose: Screening
Time Perspective: Cross-Sectional
Time Perspective: Prospective
Official Title: Effects of Allergen Inhalation on Adenosine Receptor Expression and Mast Cell Activation in Peripheral Blood and Sputum of Asthmatics and Healthy Subjects

Resource links provided by NLM:

MedlinePlus related topics: Asthma
Drug Information available for: Adenosine
U.S. FDA Resources

Further study details as provided by Groningen Research Institute for Asthma and COPD:

Estimated Enrollment: 20
Study Start Date: July 2005
Estimated Study Completion Date: February 2007
  Eligibility

Ages Eligible for Study:   18 Years to 50 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Asthmatic Subjects - Inclusion Criteria:

  • Clinical diagnosis of asthma
  • Steroid naive or subjects not using their inhaled steroids for the last 4 weeks, short-acting beta-agonist for rescue medication
  • FEV1 > 70% of predicted
  • Positive skin prick test for house dust mite, cat or grass pollen
  • PC20 methacholine or histamine < 8 mg/ml

Asthmatic Subjects - Exclusion Criteria:

  • Use of systemic steroids in the previous 6 weeks
  • Asthma exacerbations in the previous 6 weeks
  • Current or ex-smokers with ≥ 10 pack-years (≥ 2 pipe pack-years), ex smokers who stopped less than 1 year ago

Healthy Subjects - Inclusion Criteria:

  • No airway complaints
  • FEV1 > 90% of predicted
  • Negative skin prick test
  • PC20 methacholine or histamine > 8 mg/ml

Healthy Subjects - Exclusion Criteria:

  • Use of steroids in the previous 6 weeks
  • Current or ex-smokers with ≥ 10 pack-years (≥ 2 pipe pack-years), ex smokers who stopped less than 1 year ago
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00116311

Locations
Netherlands
University Medical Center Groningen, Department of Pulmonology
Groningen, Netherlands, 9713 GZ
Sponsors and Collaborators
Groningen Research Institute for Asthma and COPD
Investigators
Principal Investigator: Dirkje S Postma, prof. MD PhD University Medical Center Groningen, Department of Pulmonology, hanzeplein 1, 9713 GZ Groningen, The Netherlands
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00116311     History of Changes
Other Study ID Numbers: METc2004-253
Study First Received: June 28, 2005
Last Updated: March 20, 2007
Health Authority: Netherlands: Dutch Health Care Inspectorate

Keywords provided by Groningen Research Institute for Asthma and COPD:
Adenosine receptors
asthma
sputum
peripheral blood
healthy

Additional relevant MeSH terms:
Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Adenosine
 Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Anti-Arrhythmia Agents
Cardiovascular Agents
Vasodilator Agents

ClinicalTrials.gov processed this record on May 19, 2013